Generalized Anxiety Disorder 7-item Scale (GAD-7)

Overview

The Generalized Anxiety Disorder 7-item scale (GAD-7) is a brief, self-administered questionnaire that screens for generalized anxiety disorder and measures the severity of anxiety symptoms over the preceding two weeks. It takes most people under three minutes to complete and has become one of the most widely used anxiety measures in both primary care and specialist practice, valued for being short enough to use at almost every visit without adding meaningful burden to the patient or the clinic.

Although named for generalized anxiety disorder, the GAD-7 performs well as a general-purpose anxiety screen — research has shown it also has reasonable sensitivity for panic disorder, social anxiety disorder, and post-traumatic stress disorder, which is part of why it has been adopted so broadly beyond GAD-specific settings.

History

The GAD-7 was developed by Robert L. Spitzer, Kurt Kroenke, Janet B.W. Williams, and Bernd Löwe, and published in 2006 in the Archives of Internal Medicine. It emerged from the same research programme that produced the PHQ family of measures (including the PHQ-9), extending that brief, criterion-based approach to anxiety.

The scale was validated in primary care patients against a structured mental health interview, and the original study found it performed strongly as both a screening tool and a severity measure — good enough that a 7-item version fully replaced longer instruments in many primary care settings. Its brevity, together with strong psychometric performance, is largely why it has since been incorporated into national screening guidelines and electronic health record templates worldwide.

Indications

The GAD-7 is used wherever anxiety symptoms need to be screened for, quantified, or tracked over time:

• Primary care screening for anxiety symptoms during routine or presenting-complaint visits.
• Vestibular and dizziness presentations, where anxiety is a common comorbidity — persistent postural-perceptual dizziness (PPPD) in particular has a well-documented bidirectional relationship with anxiety, and chronic vertigo or imbalance frequently provokes situational and anticipatory anxiety.
• Post-concussion and mild traumatic brain injury, where anxiety symptoms often accompany or outlast the physical symptoms.
• Chronic pain and chronic illness populations, where anxiety is a common but under-recognised comorbidity.
• Monitoring treatment response for anxiety, whether pharmacological, psychological, or a combination, by re-administering at intervals.

How It’s Scored

Each of the 7 items is rated on how often the symptom has bothered the respondent over the last two weeks, from 0 (not at all) to 3 (nearly every day). The total score is the sum of all 7 items, giving a range from 0 to 21.

Interpretation bands

A score of 10 or greater is a widely used threshold for flagging a probable anxiety disorder warranting further clinical assessment — the original validation study reported good sensitivity and specificity for generalized anxiety disorder at this cut-point. As with any screening threshold, it should prompt further evaluation rather than stand alone as a diagnosis.

The original instrument also includes a non-scored functional-impact question — “if you checked off any problems, how difficult have these made it for you to do your work, take care of things at home, or get along with other people?” — which isn’t included in the numeric total but adds useful context about the real-world impact of symptoms.

What It Tells the Clinician

• Flags probable anxiety quickly. A three-minute questionnaire that reliably surfaces anxiety symptoms a patient may not otherwise volunteer, especially when the presenting complaint is physical (dizziness, fatigue, pain) rather than psychological.
• Quantifies severity, not just presence. The banded score helps triage — a minimal score reassures, while a severe score can prompt more urgent follow-up or referral.
• Supports comorbidity screening in vestibular and neurological practice. Because anxiety so commonly co-occurs with chronic dizziness, post-concussion symptoms, and other neurological presentations, the GAD-7 is a useful companion to instruments like the DHI when a patient’s functional impairment seems disproportionate to objective findings.
• Tracks change over the course of treatment. Regular re-administration shows whether anxiety is improving alongside — or independently of — the primary condition being treated.
• Broad screening value beyond GAD. Elevated scores can also reflect panic disorder, social anxiety disorder, or PTSD, so a high score is a prompt for closer diagnostic assessment rather than an automatic GAD diagnosis.

References

1. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-1097.